Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carl Zeiss Meditec AGXSWX:AFX 73 Earnings per Share (Diluted) is CHF1.29 as of Dec. 2025. GuruFocus rates XSWX:AFX with a GF Score™ of 73/100 and a GF Value™ of CHF71.28 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 661 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks worse than 84.72% on this metric.
Carl Zeiss Meditec AG's EPS (Basic) for the
three
months ended in Dec. 2025 was CHF-0.06.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.29.
During the past 12 months, Carl Zeiss Meditec AG's average EPS without NRIGrowth Rate was -22.60% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -23.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -2.30% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 7.90% per year.
During the past 13 years, Carl Zeiss Meditec AG's highest 3-Year average EPS without NRI Growth Rate was 27.00% per year. The lowest was -23.30% per year. And the median was 7.20% per year.
Carl Zeiss Meditec AG (XSWX:AFX) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Carl Zeiss Meditec AG Earnings per Share (Diluted) Related Terms
Carl Zeiss Meditec AG Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG Earnings per Share (Diluted) Chart
XSWX:AFX vs ISRG, BDX, MDLN: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's PE Ratio distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's PE Ratio falls into.
Carl Zeiss Meditec AG Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Carl Zeiss Meditec AG's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of CHF1.29 mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Earnings per Share (Diluted) of CHF1.29 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Carl Zeiss Meditec AG and its competitors. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #560 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 84.7%.
Is Carl Zeiss Meditec AG's Earnings per Share (Diluted) too high?
Carl Zeiss Meditec AG's current Earnings per Share (Diluted) is CHF1.29. Based on the distribution chart, Carl Zeiss Meditec AG ranks #560 out of 661 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Carl Zeiss Meditec AG has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Earnings per Share (Diluted) compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #560 out of 661 companies for Earnings per Share (Diluted). This places Carl Zeiss Meditec AG in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.20, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current Earnings per Share (Diluted) is CHF1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF71.28, compared to a current price of CHF27.02 — trading 62.1% below its estimated fair value. The current Earnings per Share (Diluted) is CHF1.29. Carl Zeiss Meditec AG's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Earnings per Share (Diluted) is CHF1.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF27.02 is trading 62.1% below its estimated GF Value™ of CHF71.28.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
Earnings per Share (Diluted): CHF1.29
GF Value™: CHF71.28 vs. price of CHF27.02 (62.1% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
73GF Score
Get the complete analysis for XSWX:AFX
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
